2025-10-14 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data, formatted as requested.

## Johnson & Johnson (JNJ) Analysis

**Company Overview:** Johnson & Johnson is a global healthcare company engaged in the research, development, manufacture, and sale of a broad range of products in the healthcare field.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 47.00%
*   **VOO Cumulative Return:** 96.68%
*   **Absolute Divergence (Current):** -52.5%
*   **Relative Divergence:** 15.8% (Indicates the current divergence is near the lower end of its historical range compared to the S&P 500.)

**Analysis:** JNJ has significantly underperformed the S&P 500 over the analyzed period. The relative divergence suggests this underperformance is near its historical lows.

**Alpha, Beta Analysis Table:**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|------------|---------|---------|---------|--------|--------|
| 2015-2017  | 26.0%  | 66.8%  | -2.0%   | -0.1   | 336.5  |
| 2016-2018  | 14.0%  | 10.7%  | -1.0%   | 0.1    | 310.8  |
| 2017-2019  | 20.0%  | 71.5%  | -2.0%   | 0.4    | 351.3  |
| 2018-2020  | 19.0%  | 79.2%  | -4.0%   | 0.4    | 379.0  |
| 2019-2021  | 33.0%  | 79.2%  | -14.0%  | 0.5    | 412.0  |
| 2020-2022  | 8.0%   | 79.6%  | 9.0%    | 0.4    | 425.4  |
| 2021-2023  | -19.0% | 79.6%  | -20.0%  | 0.3    | 377.5  |
| 2022-2024  | -32.0% | 79.6%  | -53.0%  | 0.3    | 348.3  |
| 2023-2025  | 18.0%  | 79.6%  | -43.0%  | 0.1    | 459.8  |

*   **CAGR:** The Compound Annual Growth Rate fluctuates, with recent periods showing negative growth.
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant potential for losses.
*   **Alpha:** Alpha is mostly negative, indicating underperformance relative to its benchmark, except for the 2020-2022 period. Recent years show significant negative alpha.
*   **Beta:** Beta is generally low, suggesting JNJ is less volatile than the overall market.
*   **Cap(B):** Market capitalization fluctuates.

**Analysis:** The Alpha/Beta analysis reinforces the underperformance. The negative alpha values, particularly in recent periods, suggest that JNJ has not been generating excess returns compared to its benchmark.

### 2. Recent Stock Price Action

*   **Current Price:** $190.90
*   **Previous Close:** $190.72
*   **Change:** $0.09
*   **5-Day Moving Average:** 190.103
*   **20-Day Moving Average:** 182.8093
*   **60-Day Moving Average:** 176.8517

**Analysis:** The stock price is trading above its 5, 20, and 60-day moving averages, suggesting a short-term upward trend. The slight positive change from the previous close indicates minimal recent movement.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 96.47 (Overbought)
*   **PPO:** 0.3652
*   **Hybrid Signal:** Buy (688 shares - Very Safe)
*   **Recent (20-day) Relative Divergence Change:** 3.4 (+) (Short-term increase)
*   **Expected Return:** -109.7%

**Analysis:**

*   The RSI indicates that JNJ is currently overbought and may be due for a correction.
*   The MRI suggests a medium level of investment risk.
*   Despite the high RSI, the Hybrid Signal recommends a "Buy" based on a "Very Safe" assessment.
*   The positive change in relative divergence indicates a recent improvement in JNJ's performance compared to its benchmark.
*   The negative expected return is concerning, suggesting significant potential underperformance relative to the S&P 500 over the long term.
*   {'price': 190.9, 'previousClose': 190.72, 'change': 0.09}: The price change is very minimal, indicating no significant market-moving event at the immediate close.

### 4. Recent News & Significant Events

*   **Earnings Season Preview:** JPMorgan, Citi, and other Wall Street banks leading off Q3 earnings season.  (Broad market context, not specific to JNJ).
*   **Protagonist Therapeutics:**  J&J reportedly eyeing a deal, causing Protagonist's stock to surge. This suggests J&J is actively pursuing acquisitions to bolster its pipeline.
*   **Ardelyx CFO Appointment:** Ardelyx appoints Sue Hohenleitner as Finance Chief. (Indirectly relevant; could indicate broader healthcare sector activity/personnel changes).
*   **J&J MedTech Segment:**  Analysis of J&J's MedTech segment growth prospects.  (Directly relevant; provides insight into a key business segment).

**Analysis:** The news suggests J&J is actively exploring strategic acquisitions (Protagonist Therapeutics). The focus on the MedTech segment indicates its importance to JNJ's overall performance.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 2.12)
*   **Opinions:** 22
*   **Target Price:** Average: $187.49, High: $213.00, Low: $155.00
*   **Recent Rating Changes:** No specific changes provided.

**Analysis:** Analysts have a generally positive outlook on JNJ, with a consensus "Buy" rating. However, the average target price is slightly *below* the current price, suggesting limited upside potential, and potential downside. The range of target prices is wide, indicating uncertainty among analysts.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-07-24 | 2.3  | 23.74 B$ |
| 2025-04-23 | 4.57 | 21.89 B$ |
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2025-07-24 | 1.95 | 22.45 B$ |

**Analysis:**  Earnings per share (EPS) and revenue figures have fluctuated. There is no clear consistent trend. The most recent quarter (2025-07-24) showed relatively strong revenue but moderate EPS. The duplicated entry for 2025-07-24 makes the analysis difficult and calls for clarification.

### 6. Financial Information:

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $23.74B    | 67.87%        |
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |
| 2024-06-30   | $22.45B    | 69.40%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE     |
|--------------|------------|---------|
| 2025-06-30   | $78.47B    | 7.06%   |
| 2025-03-31   | $78.11B    | 14.08%  |
| 2024-12-31   | $71.49B    | 4.80%   |
| 2024-09-30   | $70.16B    | 3.84%   |
| 2024-06-30   | $71.54B    | 6.55%   |

**Analysis:**

*   **Revenue:**  Revenue has been relatively stable over the past five quarters, with the most recent quarter showing a slight increase.
*   **Profit Margin:** Profit margins are consistently high, indicating strong operational efficiency.
*   **Equity:**  Equity has generally increased over the period.
*   **ROE:**  Return on Equity (ROE) has fluctuated, with the highest value in Q1 2025.

### 7. Summary & Conclusion

Overall, the analysis presents a mixed picture of Johnson & Johnson.

*   **Underperformance:** JNJ has significantly underperformed the S&P 500 over the analyzed period, and its alpha values are primarily negative.
*   **Recent Positive Signals:** The stock is trading above its moving averages, and the short-term relative divergence has increased.
*   **Overbought Condition:** The RSI indicates that the stock is overbought.
*   **Analyst Sentiment:** Analysts have a generally positive outlook ("Buy"), but the average target price is below the current price.
*   **Financial Health:** Revenue and profit margins are strong, indicating solid financial health.
*   **Strategic Activity:** Recent news suggests J&J is actively seeking acquisitions.
*   **Concerning Expected Return:** The negative expected return (-109.7%) raises concerns about the potential for long-term underperformance compared to the S&P 500.

**Recommendation:** While JNJ appears to be in solid financial condition, its historical underperformance, overbought technicals, and negative expected return warrant caution. A potential investor should carefully weigh these factors and consider whether JNJ aligns with their investment goals and risk tolerance. Further research into the reasons for the underperformance and the company's future growth strategies is recommended. The duplicated earnings data should also be clarified.
